One study found that ERK1/2 – an intermediate of the GDNF pathway that leads to activation of FOS and other target genes, was increasingly phosphorylated in more than half of 26 seminomas potentially altering expression of downstream targets of the RAS/ERK1/2 pathway including FOS and ATF (Goriely et al., 2009). The gene discussed is FOS; the disease is seminoma.